



DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention

Notice of Award

Award# 5 NH25PS005141-03-00
FAIN# NH25PS005141
Federal Award Date: 12/14/2020

Recipient Information

1. Recipient Name

San Francisco Department of Public Health
101 GROVE ST
San Francisco Department of Public Health
SAN FRANCISCO, CA 94102-4505
[NO DATA]

2. Congressional District of Recipient

12

3. Payment System Identifier (ID)

1946000417A8

4. Employer Identification Number (EIN)

946000417

5. Data Universal Numbering System (DUNS)

103717336

6. Recipient's Unique Entity Identifier

7. Project Director or Principal Investigator

Dr. Tomas Aragon.
Health Officer and Director, Population Health
Division
tomas.aragon@sfdph.org

8. Authorized Official

Maggie Han
Deputy Director of Finance
maggie.han@sfdph.org
628-206-7681

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Ms. Portia Brewer
Grants Management Officer
yfa2@cdc.gov
770-488-3185

10. Program Official Contact Information

Ms. Britney Johnson
mwq4@cdc.gov
404.718.5604

Federal Award Information

11. Award Number

5 NH25PS005141-03-00

12. Unique Federal Award Identification Number (FAIN)

NH25PS005141

13. Statutory Authority

This Program is authorized under section 318 of the Public Health Service Act (42 U.S.C. Section 247c, as amended)

14. Federal Award Project Title

Strengthening STD Prevention and Control for Health Departments (STD PCHD)

15. Assistance Listing Number

93.977

16. Assistance Listing Program Title

Preventive Health Services_Sexually Transmitted Diseases Control Grants

17. Award Action Type

Non-Competing Continuation

18. Is the Award R&D?

No

Summary Federal Award Financial Information

19. Budget Period Start Date 01/01/2021 - **End Date** 12/31/2021

20. Total Amount of Federal Funds Obligated by this Action \$1,116,104.00

20a. Direct Cost Amount \$1,098,450.00

20b. Indirect Cost Amount \$17,654.00

21. Authorized Carryover \$0.00

22. Offset \$0.00

23. Total Amount of Federal Funds Obligated this budget period \$0.00

24. Total Approved Cost Sharing or Matching, where applicable \$0.00

25. Total Federal and Non-Federal Approved this Budget Period \$1,116,104.00

26. Project Period Start Date 01/01/2019 - **End Date** 12/31/2023

27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period \$3,352,582.00

28. Authorized Treatment of Program Income

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Mr. Arthur Lusby
Grants Management Officer, Team Lead

30. Remarks

Non-Competing Continuation: Financial Assistance in the amount of \$1,116,104.00



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award

Award# 5 NH25PS005141-03-00

FAIN# NH25PS005141

Federal Award Date: 12/14/2020

Recipient Information

Recipient Name

San Francisco Department of Public Health
101 GROVE ST
San Francisco Department of Public Health
SAN FRANCISCO, CA 94102-4505
[NO DATA]

Congressional District of Recipient

12

Payment Account Number and Type

1946000417A8

Employer Identification Number (EIN) Data

946000417

Universal Numbering System (DUNS)

103717336

Recipient's Unique Entity Identifier

Not Available

31. Assistance Type

Cooperative Agreement

32. Type of Award

Other

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages	\$630,507.00
b. Fringe Benefits	\$252,203.00
c. Total Personnel Costs	\$882,710.00
d. Equipment	\$0.00
e. Supplies	\$6,542.00
f. Travel	\$19,448.00
g. Construction	\$0.00
h. Other	\$28,080.00
i. Contractual	\$161,670.00
j. TOTAL DIRECT COSTS	\$1,098,450.00
k. INDIRECT COSTS	\$17,654.00
l. TOTAL APPROVED BUDGET	\$1,116,104.00
m. Federal Share	\$1,116,104.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-9210840	19NH25PS005141	PS	41.51	\$114,990.00	75-21-0950
1-939ZRPZ	19NH25PS005141	PS	41.51	\$1,001,114.00	75-21-0950



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 5 NH25PS005141-03-00

FAIN# NH25PS005141

Federal Award Date: 12/14/2020

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 5 NH25PS005141-03-00

FAIN# NH25PS005141

Federal Award Date: 12/14/2020

35. Terms And Conditions

Federal Financial Report Cycle			
Reporting Period Start Date	Reporting Period End Date	Reporting Type	Reporting Period Due Date
01/01/2019	12/31/2019	Annual	03/30/2020
01/01/2020	12/31/2020	Annual	09/25/2020
01/01/2021	12/31/2021	Annual	03/31/2022

AWARD ATTACHMENTS

San Francisco Department of Public Health

5 NH25PS005141-03-00

1. Terms and Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number **CDC-RFA-PS19-1901**, entitled **“Strengthening STD Prevention and Control for Health Departments (STD PCHD)”**, and application dated **August 27, 2020**, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Approved Funding: Funding in the amount of **\$1,116,104** is approved for the Year **03** budget period, which is **January 1, 2021** through **December 31, 2021**. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Note: Refer to the Payment Information section for draw down and Payment Management System (PMS) subaccount information.

This award has been fully funded for budget year 03.

Financial Assistance Mechanism: Cooperative Agreement

Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

In a cooperative agreement, CDC staff are substantially involved in the program activities, above and beyond routine grant monitoring. CDC activities for this program are as follows:

Technical assistance and capacity building

- Work with recipients to identify capacity building assistance and technical assistance (TA) needs that are essential to the success of the project
- Provide access to training and TA, including via CDC-TRAIN, that will strengthen staff capacity relevant to all required strategies and activities of the program
- Assist recipients with enhancing health department workforce capacity and infrastructure by providing training and TA around skills assessment, core competencies and workforce development
- Provide STD clinical and laboratory consultation and STD reference diagnostic services
- Collaborate in assessing progress toward meeting strategic and operational goals/objectives and in establishing measurement and accountability systems for documenting outcomes, such as increased performance improvements and best or promising practices

Information sharing

- Facilitate coordination, collaboration, and, where feasible, service integration among federal agencies, other CDC funded programs, other health departments, community based organizations, local and state planning groups, other CDC directly funded programs, medical care providers, laboratories, and others addressing STD prevention and control activities
- Collaborate to compile and disseminate accomplishments, best practices, performance criteria, and lessons learned during the period of performance
- Share information, best practices, lessons learned, and evaluation results among recipients through, for example: conferences, guidance, material development, webinars, data sharing publications, committees, conference calls, and working groups

Award guidance and monitoring

- Support recipients in implementing the requirements of the cooperative agreement, selecting or prioritizing prevention strategies/activities and meeting identified outcomes
- Monitor recipients' program performance using multiple approaches, such as routine calls, site visits, emails, conference calls, affinity group participation, and standardized review of performance, grantee feedback and other data reports
- Provide guidance and coordination to recipients to improve the quality and effectiveness of work plans, evaluation strategies, products and services, and collaborative activities with other organizations
- Provide requirements and expectations for standardized and other data reporting, monitoring, and evaluation

Expanded Authority: The recipient is permitted the following expanded authority in the administration of the award.

- ☒ Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of unobligated funds in Section 12 "Remarks" of the annual Federal Financial Report. If the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient's authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of these actions.

Program Income: Addition alternative: Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

The disposition of program income must have written prior approval from the GMO.

FUNDING RESTRICTIONS AND LIMITATIONS

Notice of Funding Opportunity (NOFO) Restrictions:

- Recipients may not use funds for research.
- Recipients may not use funds for clinical care except as allowed by law.
- Recipients may use funds only for reasonable program purposes, including personnel,

- travel, supplies, and services.
- Generally, recipients may not use funds to purchase furniture or equipment. Any such proposed spending must be clearly identified in the budget.
- Reimbursement of pre-award costs generally is not allowed, unless the CDC provides written approval to the recipient.
- Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any cooperative agreement or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body.
- See [Additional Requirement \(AR\) 12](http://www.cdc.gov/grants/additionalrequirements/index.html#ar12) (<http://www.cdc.gov/grants/additionalrequirements/index.html#ar12>) for detailed guidance on this prohibition and [additional guidance on lobbying for CDC recipients](http://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf) (http://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf).
- The direct and primary recipient in a cooperative agreement program must perform a substantial role in carrying out project outcomes and not merely serve as a conduit for an award to another party or provider who is ineligible.
- In accordance with the United States Protecting Life in Global Health Assistance policy, all non-governmental organization (NGO) applicants acknowledge that foreign NGOs that receive funds provided through this award, either as a prime recipient or subrecipient, are strictly prohibited, regardless of the source of funds, from performing abortions as a method of family planning or engaging in any activity that promotes abortion as a method of family planning, or to provide financial support to any other foreign non-governmental organization that conducts such activities. See Additional Requirement (AR) 35 for applicability (<https://www.cdc.gov/grants/additionalrequirements/ar-35.html>).

Funding restrictions specific to this NOFO

- Recipients may not use funds to purchase HIV Pre-exposure Prophylaxis (PrEP) medications or family planning medications.
- Recipients may not use funds to purchase STD medications, other than noted in this NOFO, unless they receive prior approval from CDC.
- STD-related HIV prevention activities should be conducted under this cooperative agreement, but they should not exceed ten percent (10%) of program effort and allocation.
- Applicants may provide assistance, no more than 10% of the overall amount, without prior approval from CDC, to not-for-profit or government clinics that can document their ability to provide safety-net STD clinical preventive services as per CDC guidance.

Indirect Costs: Indirect costs are approved based on the recipient's approved Cost Allocation Plan dated **March 13, 2020**.

REPORTING REQUIREMENTS

Annual Federal Financial Report (FFR, SF-425): The Annual Federal Financial Report (FFR) SF-425 is required and must be submitted to your GMS/GMO no later than 90 days after the end of the budget period. To submit the FFR, login to www.grantsolutions.gov, select “Reports” from the menu bar and then click on Federal Financial Reports. The FFR for this budget period is due by **March 31, 2022**. Reporting timeframe is **January 1, 2021** through **December 31, 2021**. The FFR should only include those funds authorized and disbursed during the timeframe covered by the report.

Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, the recipient is required to contact the Grants Officer listed in the contacts section of this notice before the due date.

Annual Performance Progress Reporting: The Annual Performance Progress and Monitoring Report (is due no later than 120 days prior to the end of the budget period, **August 31, 2021**, and serves as the continuation application for the follow-on budget period. This report should include the information specified in the solicitation from the GMS/GMO via www.grantsolutions.gov.

Performance Progress and Monitoring: Performance information collection initiated under this grant/cooperative agreement has been approved by the Office of Management and Budget under **OMB Number 0920-1132, “Performance Progress and Monitoring Report”** (or, **Expiration Date 10/31/2022**. The components of the PPMR are available for download at: <https://www.cdc.gov/grants/alreadyhavegrant/Reporting.html> .

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services

Portia R. Brewer, Grants Management Officer/Specialist
Centers for Disease Control and Prevention
Infectious Diseases Services Branch
2939 Flowers Rd.
Mailstop: TV-2
Fax: N/A
Email: pbrewer@cdc.gov (Include “Mandatory Grant Disclosures” in subject line)

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator
330 Independence Avenue, SW

Cohen Building, Room 5527
Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or

Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Prior Approval: All requests, which require prior approval, must bear the signature of the authorized organization representative. The recipient must submit these requests by **August 31, 2021**. Additionally budget and a narrative justification of the request. budget and a narrative justification of the request.

The following types of requests require prior approval:

- Lift funding restriction
- Significant redirection of funds (i.e. cumulative changes of 25% of total award)
- Change in scope
- Implement a new activity or enter into a sub-award that is not specified in the approved budget
- Apply for supplemental funds
- Change in key personnel
- Extensions to period of performance

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PROGRAM OR FUNDING GENERAL REQUIREMENTS

HIV Program Review Panel Requirement: All written materials, audiovisual materials, pictorials, questionnaires, survey instruments, websites, educational curricula and other relevant program materials must be reviewed and approved by an established program review panel. A list of reviewed materials and approval dates must be submitted to the CDC Grants Management Specialist identified in the CDC Roles and Responsibilities section of this NoA.

Templates for prior approval requests can be found at:

<http://www.cdc.gov/grants/alreadyhavegrant/priorapprovalrequests.html>

Templates for prior approval requests can be found at:

<http://www.cdc.gov/grants/alreadyhavegrant/priorapprovalrequests.html>.

Additional information on the electronic grants administration system CDC non-research awards utilize, Grants Solutions, can be found at:

<https://www.cdc.gov/grants/grantsolutions/index.html>.

Key Personnel: In accordance with 45 CFR Part 75.308, CDC recipients must obtain prior approval from CDC for (1) change in the project director/principal investigator, business official, authorized organizational representative or other key persons specified in the NOFO, application or award document; and (2) the disengagement from the project for more than three months, or a 25 percent reduction in time devoted to the project, by the approved Project Director or Principal Investigator.

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the “**P** Account”. Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of page 2, item #34 of this Notice of Award, must be known in order to draw-down funds.

CDC Staff Contacts

Grants Management Specialist: The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

The GMS contact information is located on page 1, item #9.

Program/Project Officer: The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

The PO contact information is located on page 1, item #10.

Grants Management Officer: The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.

The GMO contact information is located on page 1, item #29.